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A B S T R A C T
The natural history of primary eosinophilia remains highly variable and is characterized by underlying disease
heterogeneity. Chronic eosinophilic leukemia, not otherwise speciﬁed (CEL-NOS) is a rare and aggressive disease
characterized by non-speciﬁc cytogenetic abnormalities or elevated blasts, with high risk of transformation to
acute leukemia. We describe a case of CEL-NOS with two hierarchically related non-speciﬁc cytogenetic re-
arrangements, associated with an NPM1 mutation and followed by evolution to secondary AML. NPM1 muta-
tions are not previously described in CEL-NOS.
1. Introduction
Hypereosinophilia (HE) (> 1.5× 103/µL) can be observed in a
wide range of diseases and can lead to severe organ damage, as a result
of eosinophilic inﬁltration in peripheral tissues and release of granules.
Most eosinophilia is reactive, secondary to atopic conditions, infections,
medication, auto-immune disorders and/or malignancies and is caused
by overproduction of eosinophilopoietic cytokines such as interleukin 3
(IL-3), interleukin 5 (IL-5) or granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) [1].
Primary HE is caused by clonal proliferation of eosinophils and is
associated with myeloid or lymphoid neoplasms [2]. Its natural history
remains highly variable, given the underlying disease heterogeneity.
Eosinophilia associated with non-speciﬁc clonal or molecular abnorm-
alities and/or increased marrow blasts (between 5% and 20%), termed
chronic eosinophilic leukemia, not otherwise speciﬁed (CEL-NOS)
should be distinguished from myeloid/lymphoid neoplasms associated
with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or
with a PCM1-JAK2 fusion. In cases without evidence for clonal pro-
liferation, a diagnosis of idiopathic hypereosinophilic syndrome (HES)
is made, which is a diagnosis of exclusion [3].
Primary HE has an age-adjusted incidence rate of approximately
0.036 per 100.000 [4]. Eosinophilia's with recurrent genetic
abnormalities comprise only a minority of these patients (FIP1L1-
PDGFRA fusion has a median frequency of 23%). Thus, in the majority
of patients no cytogenetic aberration can be found, demonstrating the
need for molecular markers to further delineate this category [3].
We present here a case of CEL-NOS, associated with two rare, non-
speciﬁc clonal rearrangements and rapid evolution to acute myeloid
leukemia (AML).
2. Case report
A 68–year old female patient was referred to a tertiary haematology
department with unexplained eosinophilia. Only a recurrent fever and
subjective impression of weight loss was present. The patient had no
history of allergies nor drug use. Clinical examination showed morbid
obesity, without signiﬁcant other ﬁndings. Repeated fecal exams ex-
cluded parasitic infections and further examinations ruled out other
organ involvement.
Complete blood count (CBC) showed leukocytosis (43.2× 103/µL)
consisting mainly of eosinophils (82%; 35424/µL) with aberrant gran-
ulation (Fig. 1a) and thrombocytopenia (34× 103/µL). Also, a slight
increase in basophils and monocytes and a left-shift with the presence
of 0.5% myeloblasts was noted. Biochemistry showed elevated vitamin
B12 (1790 ng/L [197–866]) and LDH (689 U/L [105–233]) levels,
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whereas serum tryptase (9.73 µg/L [< 11.4]) and IgE (14.23 kU/L
[0–100]) levels were normal.
Bone marrow (BM) ﬁndings included a hypercellular marrow with
striking presence of eosinophils and eosinophilic precursors with
aberrant (mixed) granulation (Fig. 1b). Also an increased number of
myeloblasts was observed (9%). Cytogenetic analysis revealed an ab-
normal karyotype (46,XX,t(7;15)(p22;q22) [4] /46,XX,idem,t(5;12)
(q31;p11.2) [6]) with two hierarchically related abnormal rearrange-
ments. As PDGFRB is located on the long arm of chromosome 5, a
PDGFRB rearrangement was suspected and therapy with imatinib was
started. However, ﬂuorescence in situ hybridization (FISH) using break-
apart probes (Leica Microsystems) excluded both FIP1L1-PDGFRA and
PDGFRB rearrangements. To exclude rare PDGFRB translocations, we
analyzed the PDGFRB expression level, which serves as a generic
marker for the presence of PDGFRB gene fusions [5], but no signiﬁcant
overexpression was observed. In a further search for the genes involved
in the t(5;12) translocation, the patient also tested negative for the
presence of ACSL6-ETV6 fusions, previously described in patients with
AML with eosinophilia harboring a t(5;12) translocation [6]. We used
the same primers as described in [7], so only the presence of those
fusions could be excluded in this patient. Therapy with imatinib showed
no eﬀect and the patient was switched to hydroxyurea and later in-
terferon-α in combination with corticosteroids.
Five months after the initial diagnosis of CEL-NOS, the patient was
re-hospitalized, due to rapid deterioration and generalized weakness.
BM aspirate conﬁrmed eosinophilia and revealed mild dysplasia in the
erythroid lineage together with an elevated number of myeloblasts
(21%) with Auer rods, leading to a diagnosis of secondary AML (Fig. 1c-
d). Cytogenetic analysis revealed the same abnormal karyotype. Next-
generation sequencing (NGS) with an in-house developed myeloid
panel of 15 genes showed a type A mutation in NPM1 (c.860_863dup)
with a high variant allele frequency (VAF) of 47%, a missense mutation
in the conserved domain 1 of TET2 (c.4075C>T) with a VAF corre-
sponding to a heterozygous mutation in the myeloid blasts (VAF: 9%)
and a FLT3-TKD (tyrosine kinase domain) mutation (c.2505T>A; VAF:
3%), present in a minor clone. Therapy with Decitabine was started.
The patient completed 4 cycles of Decitabine, during which the
pancytopenia continued, with persistent eosinophilia (500–1000/µL)
and intermittent appearance of myeloblasts, suggesting only minor
eﬀects from this hypomethylating therapy. Unfortunately, no formal re-
evaluation could be performed as the patient passed away due to head
trauma and progressive subdural hematoma.
3. Discussion
The diagnosis of primary HE relies on the combined evaluation of
blood cell counts and morphology, biochemistry, BM morphology, im-
munophenotyping, genetic and molecular analyses. Elevated serum
tryptase (30 ng/mL on average) and vitamin B12 (often> 2000 pg/mL)
with normal IgE can help to distinguish it from reactive causes [7].
Morphologic and cytogenetic analyses of BM aspirate are warranted to
diagnose genetically-deﬁned eosinophilic neoplasms. Rapid identiﬁca-
tion of myeloid neoplasms with PDGFRA or PDGFRB rearrangement
using both FISH and PCR is needed to timely initiate therapy with
imatinib [7,8].
The diagnostic criteria of CEL-NOS are: persistent eosinophilia
greater than 1500/µL, no deﬁnitive features of other myeloid neo-
plasms, and the presence of either increased blasts or a non-speciﬁc
clonal genetic abnormality. In this case, two hierarchically related non-
speciﬁc genetic clones could be identiﬁed. The t(7;15)(p22;q22) is
present in all mitoses and can therefore be a de novo balanced con-
stitutional translocation. Due to insuﬃcient patient material, this could
not be conﬁrmed. Translocations between chromosomes 7 and 15 are
rare in cancer, but the presence of PDGFA on chromosome 7p22, en-
coding the ligand of the PDGFRA receptor, is intriguing. Theoretically,
the translocation could increase PDGFA expression and lead to an ac-
tivation of this signaling pathway, through an alternative mechanism as
compared to the classical rearrangements of the PDGFRA and PDGFRB
receptors.
It was ﬁrst thought that the additional t(5;12)(q31;p11.2) led to a
PDGFRB fusion, as this gene is located close to the breakpoint on 5q.
However, this could not be conﬁrmed, neither by FISH nor by PCR.
Using PCR, we also excluded the presence of an ACSL6-ETV6 fusion,
previously described in patients with AML and eosinophilia harboring a
t(5;12) translocation. Several genes encoding eosinophilopoietic cyto-
kines (GM-CSF, IL-3, IL-4 and IL-5) also reside in this genomic region
(5q31–33), which could be aﬀected by this translocation. Previous
studies showed IL-3 to be ectopically expressed in leukemic cells with a
Fig. 1. (a) Peripheral blood smear showing
eosinophilia with eosinophilic precursors,
aberrant granulation, and vacuolisation (May-
Grunwald-Giemsa staining, 500×). (b) Bone
marrow aspirate showing hypercellular
marrow with striking presence of eosinophils
and eosinophil precursors with dysplastic fea-
tures, abnormal nuclei and aberrant mixed
granulation (May-Grunwald-Giemsa staining,
500×). (c and d) Bone marrow aspirate ﬁve
months after the initial diagnosis of CEL
showing increased number of myeloblasts with
presence of Auer rods and mild dysplasia in the
erythroid lineage (May-Grunwald-Giemsa
staining, 500×).
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t(5;12)(q31;p13), suggesting that the expression of IL-3 was deregu-
lated by this translocation [9]. Interestingly, this region has been linked
to familial eosinophilia [10], but the responsible genes are not yet
identiﬁed. At the time of transformation to secondary AML, the sample
contained a NPM1 mutation at a high frequency, suggestive of a het-
erozygous mutation in all cells. Retrospective analysis of the sample
from the initial CEL-NOS diagnosis also showed the presence of the
NPM1 mutation at a high level. A review of the literature could not
detect a clear link between NPM1mutation and eosinophilia, so the role
of this mutation remains puzzling, especially as NPM1 is located distal
to the breakpoint on 5q. In contrast, mutations in TET2 are more
common in CEL-NOS, although their relevance to the disease is unclear.
In general, patients with CEL-NOS have a poor prognosis. One small
case series of 10 patients showed a median overall survival of 22
months with ﬁve patients transforming to acute leukemia [11]. Trans-
formation occurred both to myeloid and lymphoblastic acute leukemia
and the median time from acute transformation to death was only two
months (range, 1.0–6.1) [11].
No standard of care exists for the treatment of CEL-NOS. Response
to imatinib is uncommon but reported. Hydroxyurea may be useful in
selected patients to control hyperleukocytosis, eosinophilia and sple-
nomegaly. In therapy refractory patients, interferon-α has been re-
ported to induce remission in cases with translocations with a 5q31–33
breakpoint. In some cases allogeneic hematopoietic stem cell trans-
plantation induced long-term remission [7].
As the patient was not ﬁt enough to undergo classical induction
chemotherapy after transformation to AML, we started treatment with
hypomethylating agents. To our knowledge, this is the ﬁrst report of
treatment with a hypomethylating agent for AML arising from CEL-
NOS. Unfortunately, the patient died from head trauma four months
after the start of treatment, before formal re-evaluation could be per-
formed.
4. Conclusion
Accurate diagnosis is critical for eﬀective management of eosino-
philia and consists of peripheral blood and bone marrow examination.
Rapid identiﬁcation of PDGFRA or PDGFRB rearrangement using both
FISH and PCR is warranted to timely initiate therapy with imatinib.
CEL-NOS is a rare and aggressive disease with high rate of transfor-
mation to acute leukemia and resistance to conventional treatment.
Whereas hydroxyurea may be useful to control hyperleukocytosis and
splenomegaly, allogeneic stem-cell transplantation remains the only
curative option, but is only available for younger and ﬁt patients.
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